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ICD-10 diagnoses and medications) was assessed during the
12-months following AAP initiation. Cohorts with and without EPS
were defined. Demographics, clinical characteristics, and healthcare
resource use and costs over 12 months following the first EPS claim
(EPS) or randomly assigned index date (Non-EPS) were assessed.
Results. A total of 11,642 patients with schizophrenia were
identified; 21.2% developed EPS in the 12-months following
AAP initiation. EPS and Non-EPS cohorts included 2,295 (mean
age 38, 61% male, CCI 0.6) and 5,607 (mean age 39, 57% male,
CCI 0.7) patients, respectively. Over the 12-month post-index
period, EPS cohort had significantly higher rates of all-cause
(30.2% vs. 24.6%, p<0.001) and schizophrenia-related hospitalizations (22.5% vs. 12.9%, p<0.001) and schizophrenia-related
emergency room visits (25.5% vs. 16.7%, p<0.001) compared to
Non-EPS cohort. All-cause ($25,911 vs. $21,550, p<0.001) and
schizophrenia-related healthcare costs ($12,134 vs. $6,230,
p<0.001) were significantly higher in EPS vs. Non-EPS cohort.
Conclusions. In the 12 months following AAP initiation, over
20% of schizophrenia patients developed EPS, which was associated with increased healthcare resource utilization and costs.
Treatment options that minimize EPS may reduce the economic
burden of schizophrenia.
Funding. Sunovion Pharmaceuticals Inc.
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Abstract
Background. The internet allows easy access for the sales of
psychoactive agents that are not regulated by the FDA. Some of
those agents are used to help manage anxiety, depression and
sleep, such as tianeptine, etizolam, and phenibut. These medications have the potential for abuse and potentially leading to
altered mental status when intoxicated or withdrawing. This
presents a challenge to clinicians who may not be aware of
availability of such substances. Available literature has discussed
the use of above substances individually, but how do you treat if
there is use of more than one substance with different mechanisms of actions? Here we present a case of an adult male who has
used all three agents simultaneously, leading to a hospital admission.

Case History. A 32-year-old male presented to the emergency
department (ED) for altered mental status (AMS). He has a
documented history of anxiety but was never treated with
prescription medications. No history of substance use was
documented. He was self-medicating with concurrent use of
tianeptine (atypical antidepressant with mu agonist properties,)
phenibut (GABA mimetic) and etizolam (a benzodiazepine-like
agent). During his stay, he was agitated and delirious with
reports of visual hallucinations. Neuroimaging and lab studies
were within normal limits, EEG showed no seizure activity.
Over the course of his hospital stay, he was started on Depakote
for agitation, a Valium taper for suspected benzodiazepine
withdrawal and prevention of seizures, Seroquel for delirium,
and baclofen for suspected GABAergic withdrawal symptoms.
The patient’s AMS improved and he was discharged on hospital
day 10.
Conclusions. This case illustrates the difficulty managing
poly-substance use/abuse and stresses the importance for
physicians to screen for psychoactive agents purchased over
the internet or over the counter to improve treatment outcomes. Continued discussions with patients regarding risks/
benefits of use of such substances would be beneficial and help
increase awareness.
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Abstract
Background. Pharmacogenomic testing has emerged to aid medication selection for patients with major depressive disorder
(MDD) by identifying potential gene-drug interactions (GDI).
Many pharmacogenomic tests are available with varying levels
of supporting evidence, including direct-to-consumer and
physician-ordered tests. We retrospectively evaluated the safety
of using a physician-ordered combinatorial pharmacogenomic
test (GeneSight) to guide medication selection for patients with
MDD in a large, randomized, controlled trial (GUIDED).
Materials and Methods. Patients diagnosed with MDD who had
an inadequate response to ≥1 psychotropic medication were randomized to treatment as usual (TAU) or combinatorial pharmacogenomic test-guided care (guided-care). All received
combinatorial pharmacogenomic testing and medications were
categorized by predicted GDI (no, moderate, or significant GDI).
Patients and raters were blinded to study arm, and physicians were
blinded to test results for patients in TAU, through week 8. Measures included adverse events (AEs, present/absent), worsening
suicidal ideation (increase of ≥1 on the corresponding HAMD17 question), or symptom worsening (HAM-D17 increase of
≥1). These measures were evaluated based on medication changes
[add only, drop only, switch (add and drop), any, and none] and
study arm, as well as baseline medication GDI.
Results. Most patients had a medication change between baseline
and week 8 (938/1,166; 80.5%), including 269 (23.1%) who added
only, 80 (6.9%) who dropped only, and 589 (50.5%) who switched
medications. In the full cohort, changing medications resulted in
an increased relative risk (RR) of experiencing AEs at both week
4 and 8 [RR 2.00 (95% CI 1.41–2.83) and RR 2.25 (95% CI 1.39–
3.65), respectively]. This was true regardless of arm, with no
significant difference observed between guided-care and TAU,
though the RRs for guided-care were lower than for TAU. Medication change was not associated with increased suicidal ideation
or symptom worsening, regardless of study arm or type of medication change. Special attention was focused on patients who
entered the study taking medications identified by pharmacogenomic testing as likely having significant GDI; those who were
only taking medications subject to no or moderate GDI at week
8 were significantly less likely to experience AEs than those who
were still taking at least one medication subject to significant GDI
(RR 0.39, 95% CI 0.15–0.99, p=0.048). No other significant differences in risk were observed at week 8.
Conclusion. These data indicate that patient safety in the combinatorial pharmacogenomic test-guided care arm was no worse than
TAU in the GUIDED trial. Moreover, combinatorial
pharmacogenomic-guided medication selection may reduce some
safety concerns. Collectively, these data demonstrate that combinatorial pharmacogenomic testing can be adopted safely into clinical
practice without risking symptom degradation among patients.
Funding. Myriad Neuroscience/Assurex Health
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Abstract
Objectives. Olanzapine effectively treats schizophrenia and bipolar
I disorder (BD-I); however, its use is hindered by significant weight
gain. A combination of olanzapine and samidorphan (OLZ/SAM) is
in development to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain through opioid-receptor
blockade. Here, we summarize OLZ/SAM clinical data.
Methods. The OLZ/SAM development program consists of
18 phase 1–3 clinical studies evaluating antipsychotic and weight
mitigation efficacy of OLZ/SAM, along with pharmacokinetics,
safety, and tolerability. Safety evaluation also included metabolic
laboratory assessments.
Results. OLZ/SAM significantly improved psychotic symptoms
(measured by Positive and Negative Syndrome Scale); improvements were similar to that observed with olanzapine vs placebo.
OLZ/SAM resulted in significantly less weight gain than olanzapine.
Additionally, 2 long-term phase 3 extension studies confirmed the
durability of antipsychotic effect, as well as stabilization of weight
and metabolic parameters in those continuing treatment. Supporting the potential use of OLZ/SAM in BD-I, OLZ/SAM or olanzapine
resulted in bioequivalent olanzapine plasma concentrations, and
OLZ/SAM did not affect lithium or valproate pharmacokinetics.
OLZ/SAM treatment had no clinically relevant effects on ECG
parameters (including QTc interval). OLZ/SAM and olanzapine
safety were similar, except for reduced weight gain with OLZ/SAM;
no additional safety risks were identified.
Conclusion. Data across 18 OLZ/SAM studies in >1600 subjects
support an antipsychotic efficacy and safety profile for OLZ/SAM
that is similar to olanzapine, with significantly less weight gain
than olanzapine. OLZ/SAM is a potential new treatment for
schizophrenia and BD-I patients needing efficacious long-term
treatment with reduced risk of weight gain.
Funding. Alkermes, Inc.
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